The FreeStyle Libre™ flash glucose
monitoring system includes a sensor which automatically measures and
continuously stores up to 8 hours of glucose readings, allowing patients to
monitor their glucose levels without the need for painful finger pricks.
Physicians play an important role in reviewing and analysing glucose data
that is available through LibreView to support patient management.
Technological advancements have improved glucose
monitoring and diabetes care, as well as empowered patients in self-care. The
introduction of continuous glucose monitoring systems (CGM), such as the
Abbott FreeStyle LibreTM, offers patients an alternative and
additional advantages to self-monitoring of blood glucose (SMBG).
In a webinar held on 27 March 2021, paediatric
endocrinology nurses Karen Blair,
Kate Davies, and Siti Zarina Yaakop shared
insights and clinical experience based
on their frontline roles in caring for patients
with central precocious puberty (CPP)
and supporting their family members.
Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Adding empagliflozin to recommended therapy in patients with heart failure with reduced ejection fraction (HFrEF) reduced the risk of HF hospitalization and slowed renal function decline, the EMPEROR-Reduced* trial showed.
An estimated 463 million adults – about one in 11 – had diabetes in 2019. These numbers are expected to rise to 700 million by 2045. Worse, one in two people are undiagnosed. [https://www.idf.org/, accessed 19 October 2020]
The most recent report by the National Health and Morbidity
Survey (NHMS) 2019 proved to be a blow to public health in Malaysia. Even with
consistent, unrelenting efforts by stakeholders and policymakers, the figures
for NCDs continue to climb.
MIMS Doctor reached out to the Director-General of Health Tan Sri Dato' Seri Dr Noor Hisham Abdullah to get up to date with the COVID-19 situation in
the country and to obtain his thoughts on the ramifications of the findings.
In this final issue of our series, join us as we
look into the upcoming results of the pivotal EMPEROR trials, which will
investigate the use of empagliflozin in patients with either preserved or
reduced ejection fraction heart failure, with or without type 2 diabetes.
Understand why heart failure has such a high clinical burden, and the great
unmet need in providing solutions for it.
In this fourth issue,
join us as we discover the unique biology Asians have with respect to diabetes.
Take a closer look at trials evaluating whether empagliflozin’s cardiovascular
and renal benefits – as analysed in Asians – are consistent with the overall
trial population, and how it addresses unmet needs.